Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian